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Abstract— There is an unmet medical need for a more 
reliable and earlier assessment of patients suspected of having a 
deep vein thrombosis.  
 
We describe a novel approach which is developing a highly 
reliable, accurate, portable and handheld prototype medical 
diagnostic device to improve radically the speed, accuracy and 
reliability with which DVT and related blood clotting 
conditions can be assessed. The device will measure whole 
blood concentration of D-dimer, a recognized biomarker of 
increased blood clotting activity, and through innovation in the 
development of a novel detection, measurement and reporting 
system, will offer the opportunity to use the test in the point of 
care setting.  
 
The device combines innovation in antibody bio-engineering 
for high specificity immunoassay-based diagnostics and 
nano/micro engineered impedimetric analysis electrodes 
incorporating a biocompatible polymer substrate with 
development of a disposable microfluidic manifold specifically 
enabling diagnostics at the point-of-first-contact. 
I. INTRODUCTION 
DIAGNOSIS and hence treatment of disease is often 
reliant on the interpretation of chemical parameters within 
biological samples. Currently many of these measurements 
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are performed in centralized laboratories, requiring 
specialized equipment and expert personnel. This approach, 
whilst delivering high quality results, can delay diagnosis 
and hence delay commencement of treatment. There is an 
emerging requirement for diagnosis to be made at point of 
first contact with the patient, requiring clinical 
measurements being made outside the laboratory using 
compact, portable devices that can be operated by non-
specialised people. This approach, known as point-of-care 
testing, is particularly applicable when there is a need for 
rapid diagnosis and fast initiation of treatment.  
 
Venous thromboembolism represents a single disease entity 
with two patterns of clinical presentation: deep vein 
thrombosis and pulmonary embolism. Deep vein thrombosis 
(DVT) is an internal clot formed in one of the body's deep 
veins, usually one of those in the leg.  If a part of the clot 
breaks free and moves into the lung, it can lead to 
pulmonary embolism (PE), an often-fatal condition. Venous 
thromboembolism afflicts an estimated 71 per 100,000 
persons yearly, and DVT and PE are major causes of 
unexpected mortality in hospitals throughout Europe [1-4].  
It is essential that diagnosis is made quickly and accurately 
and that treatment is started promptly.  
 
During 2005 the number of reported incident cases of 
DVT and PE totalled 1.3 million in France, Spain, Germany, 
Italy, United Kingdom, Japan and United States alone. This 
figure is expected to rise to 1.4 million per annum by 2011, 
due to increase in population. Within these countries it is 
estimated that healthcare systems invest up to €6.6 billion 
annually in assessment of patients suspected to be suffering 
from thromboembolitic event, whose diagnosis proves to be 
negative.  
 
Clinical practice guidelines [5-7] indicate that the 
accuracy of diagnosis of DVT/PE by measurement of D-
dimer concentration in combination with radiological or 
laboratory diagnostic tests is superior to traditional methods 
of diagnosis [8,9]. Hence, D-dimer, a recognised biomarker 
for the diagnosis of a thrombus, is routinely measured in 
hospital laboratories using a traditional ELISA technique. D-
dimer tests are generally highly sensitive but not highly 
specific, suggesting that negative tests are much more useful 
for ruling out DVT than are positive tests for ruling in DVT 
[10-13]. The negative predictive value (proportion of 
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patients with a negative test who do not have DVT) for 
patients with a negative D-dimer blood test and a low 
clinical probability of DVT is higher than 99% [13-15].  
 
However since most quantitative D-dimer tests are 
performed in the laboratory, these can generally only be 
offered in a hospital clinic hence patients cannot be fully 
assessed within primary care: they are referred for 
assessment to a secondary care setting, such as a clinic or 
hospital, where a combination of laboratory based blood test 
and expert clinical assessment is performed. This causes 
potentially life-threatening delays to diagnosis and 
commencement of treatment for patients who do indeed 
have a blood clot; it also causes unnecessary delays for 
patients who do not.  
 
An analysis of current medical diagnostic practice and 
available tests indicates that practitioners in primary care, 
such as GP surgeries and community clinics would welcome 
access to a reliable point of care D-dimer test as it would 
improve the quality of care that they can provide to their 
patients, improve DVT healthcare diagnosis and treatment 
services, and hence improve patient outcomes. 
 
Development of an innovative medical diagnostic device 
to measure whole blood D-dimer concentration at point of 
care is described. It comprises a novel immunochemical 
biosensor and detection system within a disposable cartridge 
and with a reader for data management and transfer. 
 
The development of a thin film biosensor, comprising an 
antibody captured onto the surface of a printed electrode and 
capable of measuring concentration of a biomarker in whole 
blood, is described and the development of impedimetric 
detection, with appropriate blood handling, for measurement 
of biomarkers in whole blood is discussed. Concentration of 
D-dimer antigen in a sample of whole blood is measured by 
a novel impedimetric measurement system. The biosensor 
and detection system lie within a disposable cartridge, 
containing innovative whole blood handling capabilities and 
test and data management and transfer system are held 
within a base unit. 
 
Finally, the development of a disposable liquid handling 
cartridge, with microfluidic system designed to manipulate a 
whole blood sample and capable of delivering the sample, in 
appropriate form, into the impedimetric measurement 
system, is described. 
II. DEVELOPMENT OF CLINICAL 
RECOMMENDATIONS FOR ASSESSMENT OF DVT 
AND PE 
The clinical goals addressed are as follows:  
 
(1) Are clinical prediction rules valuable for diagnosing 
DVT/PE, and how does addition of our novel D-dimer assay 
best improve the test characteristics of clinical prediction 
rules? 
(2) What are the test characteristics of D-dimer 
measurement alone when used for diagnosis or exclusion of 
DVT or PE, and how does choice of assay affect the test 
characteristics?  
(3) What are the test characteristics of D-dimer vs. 
ultrasonography and or computed axial tomography? 
 
Evaluation of the performance of the experimental model 
assay, by comparison with the known clinical status of the 
blood samples and comparison with the performance of 
existing D-dimer testing regimes, is described.  
III. DETECTION OF A BIOMARKER IN WHOLE BLOOD USING A 
THIN FILM BIOSENSOR WITH IMPEDIMETRIC DETECTION 
Whole blood D-dimer concentration is measured through 
detection of change in impedance at the measurement 
electrode as a result of binding of D-dimer molecules to  
antibodies that have been bioengineered and immobilized 
onto the electrode surface, thus creating a highly specific 
immunoassay.  
A. Development of the Biosensor 
Biosensors increasingly use thin films incorporating 
active organic molecules. These layers either interface with, 
or act as, the transduction element of the sensor. The 
immobilisation of the active molecules can take a number of 
forms; for example, as monolayers directly attached to the 
sensor, as components in thin polymer films, or immobilised 
on supports, such as nanoparticles. In electrochemical 
biosensors, the active layer is interfaced with electrodes 
which react to changes in the electronic structure of the 
active layer, and which are detected by the measurement 
electronics. These changes, which are produced by chemical 
interactions between the molecules in the active layer and 
the analyte of interest, can be detected using a number of 
measurement techniques [16]. 
 
Commonly, microelectrodes produced from suitable 
conducting materials, such as gold, platinum, and silver are 
used as the interface electrodes. However, the development 
of techniques such as nanoimprint lithography (NIL) [17], 
focused ion beam (FIB) milling [18] and laser ablation, 
complemented by high-resolution etching techniques such as 
reactive ion etching (RIE) [19], have lead to the production 
of nanoelectrodes [20]. These nanoelectrode geometries 
potentially have advantages with respect to their micro-
fabricated analogues because they have improved spatial 
resolution and reduced signal noise [21]. 
 
Interfacing of the active layer molecules to nanoelectrodes 
is not a trivial subject, and we describe our evaluation and 
selection of appropriate technique. For example, if the 
molecules can be incorporated into a monomer precursor, 
they can be immobilised onto the electrodes using 
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electropolymerisation [22]. In this case, the polymer itself 
may need to be conducting to facilitate electron transfer to 
the electrode surface [23]. Common electrically conducting 
polymers used in sensing applications include poly(pyrrole) 
[24] and poly(aniline) [25] and their derivatives. The active 
(bio)molecules can be covalently bonded to the polymers, 
using suitable coupling reactions, which may involve the use 
of reactive moieties, such as amine, acid or thiol groups, or 
simply immobilised in the polymer matrix. Positional 
control of the active layer using this technique is facile, as 
the polymer grows predominantly on the electrode surface. 
However, the addition of the supporting polymer in the 
sensing system introduces a level of complexity when 
modelling the sensors and when attempting to produce a 
number of sensors with high reproducibility. 
 
Direct immobilisation of the active (bio)molecules to the 
surface of an electrode can be completed using covalent 
bonding. One of the most commonly used techniques for this 
is the interaction between a thiol group and a gold electrode. 
For example, this technique has been extensively used for 
the immobilisation of (bio)molecules through self assembly 
[26]. Such self-assembly can be used to immobilise 
biological material [27] and can be positionally controlled 
using a soft lithography method, called micro-contact 
printing [28], down to nanometric scales [29]. The formation 
of a thiol linkage between the gold and the thiolated 
(bio)molecule means that the active molecule is directly 
linked to the electrode. Non-specific immobilisation either 
side of the electrodes should be avoided as long as the thiol 
group has no affinity for the underlying substrate. The same 
molecules can be deposited using dip-pen lithography [30]. 
 
We have produced nanoelectrodes on polymeric substrates 
and describe immobilization of active (bio)molecules using 
electropolymerisation, micro-contact printing or dip-pen 
lithography techniques, ready for incorporation of 
functionalised electrodes into our microfluidic cartridge 
system for the detection of D-dimer in whole blood at levels 
of < 300 ng/ml. A variety of data extraction approaches are 
available including the measurement of impedance across a 
number of frequencies [31]. 
B. Electrochemical Impedance Spectroscopy (EIS) label-
free detection 
To achieve a sensitivity of 1ng/ml in a range of 0-
3000ng/ml of D-dimer in whole blood there is a need to 
measure impedance change on the electrode with high 
precision.  
 
Electrochemical Impedance Spectroscopy (EIS) is a 
rapidly developing electrochemical technique for the 
characterization of biomaterial-functionalized electrodes and 
especially for the transduction of biosensing events at the 
electrodes. Experiments have indicated that antibody loaded 
electroconductive matrices (particularly polypyrrole) give 
concentration dependant responses when interrogated with 
EIS [32,33]. The electroconductive matrix presents a high 
surface concentration of grafted biomolecules and the 
change of conformation brought by biological recognition 
induces a change of the polymer conjugation, which results 
in amplification of the electrical phenomenon. A particular 
enhancement of the sensitivity of detection was observed in 
presence of redox probe [34]. EIS, under appropriate 
experimental conditions, represents a label-free technique 
for immunodetection. 
 
We have developed an approach to optimize the 
orientation control of the reduced antibody-scFV fragments 
in the electroconductive matrix. Further, we control the 
electronic exchange by inclusion of a specific redox species 
in the polymer structure, in order to enhance the sensitivity 
of detection and limit non specific adsorption onto the 
functionalised electrode surface, by grafting a specific group 
onto the pyrrole monomer. 
IV. DEVELOPMENT OF A NOVEL MICROFLUIDIC SYSTEM, 
DEVICE AND READER 
A. The Disposable Cartridge and liquid handling system 
We have designed the cartridge to ensure robustness of 
sample and reagent transfer and, therefore, focus on fluidic 
transfer properties rather than additional functionality.  
 
The cartridge is designed and fabricated using established 
technologies in polymer microfabrication. These include hot 
embossing to define the microfluidic channels and 
chambers, photolithography and nanoimprint lithography to 
structure the impedimetric electrodes and laser ablation for 
the passivation layer.  
 
Our design and choice of mass manufacturing approach 
takes into account consideration of future scalability.  
 
The nano- and microelectrodes for the impedimetric 
measurement are housed in a sample chamber that can be 
accessed from both sample and reagent reservoirs. 
 
Immobilisation of the D-dimer antibody onto the electrode 
is performed in an open cartridge configuration. This 
facilitates the immobilisation process and allows easy 
quality control of the biological receptor layers. However, it 
puts very high demand on the joining of the cartridge parts. 
We describe our choice of existing and novel joining 
processes that minimize temperature, UV and solvent load to 
the biological receptor molecules while guaranteeing robust 
functionality of the cartridge. 
B. Reader - Design and Functionality 
During the measurement phase ‘cartridge’ and ‘reader’ 
will operate as one compound system to provide all required 
functionalities. We describe, therefore, our design for the 
device as a whole, which has been conceptualized and 
developed to be user friendly, and able to be operated by 
117
Authorized licensed use limited to: Teesside University. Downloaded on May 06,2010 at 13:54:19 UTC from IEEE Xplore.  Restrictions apply. 
 
 
non-expert users, such as practitioners, paramedics and 
ultimately by patients.  
 
The reader itself is a microcontroller driven device, part of 
a complex system consisting of four component parts that, 
when combined, give rise to a device capable of measuring 
biomarker concentration under Point-of-Care conditions. 
 
We have developed an approach to drive the blood sample 
from point of entry to the electrode and then to remove the 
unwanted blood sample components (plasma, red blood 
cells, other proteins, etc.) from the measurement site. It 
relies on fluidic interconnection between cartridge and 
reader and on a micro-pump situated in the reader that will 
move buffer solution and blood sample through the 
cartridge. 
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